CD8A and neoplasm: Shen et al. reported that using vascular-disrupting agent CA4 nanomedicine to treat murine 4T1 tumor model showed no obvious increase in the CD4+ helper T cells, CD8+ cytotoxicity T cells, natural killer cells, and mature dendritic cells due to the tumor hypoxia [7].